INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
07/05/2026
Back to search
Official data from USPTO
HELSINN BUILDING QUALITY CANCER CARE TOGETHER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Quick snapshot
ST13
US500000079202865Class
1, 5, 35, 40, 42, 45
Filing
79202865
Registration
5372161
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
07/05/2026
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 35, 40, 42, 45
Filing date
10/03/2016
Registration date
01/09/2018
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/15/2025
Last transaction
07/05/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
Lugano, CH
Examiner
TRUSILO, KELLY JEAN
Current location
Historical data usage
Mark description
The mark consists of four squares forming a stylized letter "H" in blue next to and to the left of the word "HELSINN" appearing in gray. The words "BUILDING QUALITY CANCER CARE TOGETHER" appear in blue below "HELSINN".
Holders and representatives
Holders
Helsinn Healthcare SA
Helsinn Healthcare SA
Representatives
Amanda Laura Nye AMANDA NYE LAW OFFICES
Technical classification
Nice Classes
Class 1Class 5Class 35Class 40Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical substanceschemical compounds for analyses in laboratories for scientific purposesother than for medical or veterinary use
Class 5
Pharmaceutical productsanti-inflammatory drugsantiemetic drugsdrugs for the treatment of cancercarcinomaleukemialymphomamelanomaanti-tumor drugsanti-emeticanti-tumor and anticancer pharmaceutical preparations for the treatment of oncological diseases and the side effects of treatment ; drugs for use in case of ulcerative and inflammatory conditionsanti-anxiety drugsanti-migraine drugscognition enhancing drugsdrugs for the prevention and treatment of gastroenterologicalhepatologicnephrologic and cardiovascular disorders of any origin; drugs for internal cleansing purposesbowel cleansers and evacuants for medical and pharmaceutical purposesveterinary vaccines and sanitary preparations for medical purposes; dietetic foods adapted for medical use
Class 35
The bringing togetherfor the benefit of othersof a variety of goodschemical substanceschemical materials and chemical productspharmaceutical productssanitary products for medical purposesdietetic substances for medical useexcluding the transport thereofenabling customers and wholesalers to conveniently view and purchase those goods
Class 40
Treatment in the nature of chemical processing of chemicalbiochemical and pharmaceutical products for third parties ; consulting services relating to the treatment of chemicalbiochemical and pharmaceutical products; information and advisory services in the field of chemicalbiochemical and pharmaceutical products treatment and processing
Class 42
Scientific research and development of pharmaceuticals; scientific and industrial research for the development of drugs and chemical componentsas well as technical and scientific consultancy in the fields of scientific research of chemicalbiochemical and pharmaceutical technologies; engineering services including engineering surveys in the fields of chemicalbiochemical and pharmaceutical technologies; provision of technological professional knowledgeparticularly in the field of planning and design of technological development in franchising chemicalbiochemical and pharmaceutical products
Class 45
Licensing in the field of chemicalbiochemical and pharmaceutical products ; legal representation and adviceparticularly before and during national procedures for the regulation of chemicalbiochemical and pharmaceutical products
Publications
History of USPTO decisions and trademark events.
51 publications found
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
12/15/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/20/2025
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
10/24/2025
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
09/27/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
09/27/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
05/23/2025
NC71
NOTICE OF CANCELLATION SEC. 71 E-MAILED
04/15/2025
C71T
CANCELLED SECTION 71
04/15/2025
PR75
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
09/30/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/16/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/19/2024
ES75
TEAS SECTION 71 & 15 RECEIVED
12/21/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/09/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/22/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/22/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/22/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/06/2018
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
04/16/2018
XXCR
GENERIC MADRID TRANSACTION CREATED
04/16/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/09/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
01/09/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/24/2017
PUBO
PUBLISHED FOR OPPOSITION
10/24/2017
GPNX
NOTIFICATION PROCESSED BY IB
10/21/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/04/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/04/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/04/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/18/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
09/18/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/18/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
09/18/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/18/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/09/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2017
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/09/2017
CNFR
FINAL REFUSAL MAILED
08/16/2017
CNFR
FINAL REFUSAL WRITTEN
08/15/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/26/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/26/2017
ALIE
ASSIGNED TO LIE
07/20/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/15/2017
RFNT
REFUSAL PROCESSED BY IB
04/08/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/21/2017
RFRR
REFUSAL PROCESSED BY MPU
03/21/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/21/2017
CNRT
NON-FINAL ACTION WRITTEN
03/20/2017
MAFR
APPLICATION FILING RECEIPT MAILED
03/14/2017
DOCK
ASSIGNED TO EXAMINER
03/11/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/10/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/09/2017
Continuous trademark protection
Get notified about every new filing that threatens HELSINN BUILDING QUALITY CANCER CARE TOGETHER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.